Sector Update: Health Care Stocks Flat to Lower Premarket Monday

MT Newswires Live

06-23

Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the iShares Biotechnology ETF (IBB) inactive.

Novo Nordisk (NVO) said it has halted its collaboration with Hims & Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.

Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a "statistically significant" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.

Cidara Therapeutics (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545441261"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545441261\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545441261?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545441261","market":"fut","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Flat to Lower Premarket Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive.</p><p>Novo Nordisk (NVO) said it has halted its collaboration with Hims &amp; Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims &amp; Hers Health shares were down more than 23% pre-bell.</p><p>Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.</p><p>Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Flat to Lower Premarket Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Flat to Lower Premarket Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive.</p><p>Novo Nordisk (NVO) said it has halted its collaboration with Hims &amp; Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims &amp; Hers Health shares were down more than 23% pre-bell.</p><p>Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.</p><p>Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545441261","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545441261","pubTimestamp":1750684354,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund  declining 0.2% and the iShares Biotechnology ETF  inactive.Novo Nordisk  said it has halted its collaboration with Hims & Hers Health  on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.Exelixis  shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.Cidara Therapeutics  shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"行业更新：周一盘前医疗保健股持平或走低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":0.9,"EXEL":0.9,"HIMS":0.9,"IBB":0.9,"NVO":0.9,"NVO.AU":1,"XLV":0.9},"content_text":"Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the iShares Biotechnology ETF (IBB) inactive.Novo Nordisk (NVO) said it has halted its collaboration with Hims & Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.Cidara Therapeutics (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}